{"id":52688,"date":"2023-01-09T14:02:16","date_gmt":"2023-01-09T13:02:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/"},"modified":"2023-01-09T14:02:16","modified_gmt":"2023-01-09T13:02:16","slug":"clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Company unveils Avantect early cancer detection test portfolio<\/i>\n<\/p>\n<p>SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;ClearNote Health\u2122 (formerly known as Bluestar Genomics), a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer healthier lives, today announced that Chief Executive Officer Dave Mullarkey will present a company update at the 41st annual J.P. Morgan Healthcare Conference on Wednesday, January 11 at 2:30 p.m. PST. Mullarkey will discuss the company\u2019s ongoing clinical validation and commercialization efforts across a multi-test portfolio. The Avantect\u2122 early cancer detection portfolio includes the recently launched test for pancreatic cancer, available now for physician ordering in patients over 50 with Type 2 diabetes diagnosed in the past three years.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230109005189\/en\/1679727\/5\/ClearNoteHealthLogo_rgb_%281%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230109005189\/en\/1679727\/21\/ClearNoteHealthLogo_rgb_%281%29.jpg\"><\/a><\/p>\n<p>\n\u201c<!-- no quote -->Our company made tremendous progress in the last year preparing for commercialization of the Avantect Pancreatic Cancer Test, building an international distribution strategy, and planning for a multi-product portfolio,\u201d said Mullarkey. \u201c<!-- no quote -->This is an inflection point for the company as we turn our attention from validating a single test to developing, validating, and commercializing a suite of cancer detection solutions to address the needs of patients at high risk for cancers with limited screening options and poor outcomes, including pancreatic and ovarian cancers.\u201d\n<\/p>\n<p>\nCurrent trends suggest that pancreatic cancer is poised to become the second leading cause of cancer death within this decade. The Avantect Pancreatic Cancer Test, which received FDA Breakthrough Device designation in 2021, is designed to enable earlier diagnosis for high-risk patients. Launched in 2022, the test combines the most advanced epigenomic hydroxymethylation-based features, and genomic analysis with machine learning to detect the presence or absence of an abnormal pancreatic cancer signal in cell-free DNA from blood.\n<\/p>\n<p>\nFollowing a successful validation study of the Avantect Pancreatic Cancer Test from which <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clearnotehealth.com%2Fpress-release%2Fbluestar-genomics-presents-positive-results-from-validation-study-in-pancreatic-cancer-detection-at-american-pancreatic-association-apa-annual-meeting%2F&amp;esheet=53178649&amp;newsitemid=20230109005189&amp;lan=en-US&amp;anchor=data&amp;index=1&amp;md5=8578155ef0bc0897f0e9ca60a2ae5e6b\" rel=\"nofollow noopener\" shape=\"rect\">data<\/a> was presented at the American Pancreatic Association meeting in 2022, the company is currently conducting the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clearnotehealth.com%2Fpress-release%2Fbluestar-genomics-initiates-one-of-the-largest-clinical-trials-for-early-detection-of-pancreatic-cancer%2F&amp;esheet=53178649&amp;newsitemid=20230109005189&amp;lan=en-US&amp;anchor=New+Onset+Diabetes+Management+for+Earlier+Detection+%28NODMED%29+trial&amp;index=2&amp;md5=3269d457bd61de923a3e86f6381c561d\" rel=\"nofollow noopener\" shape=\"rect\">New Onset Diabetes Management for Earlier Detection (NODMED) trial<\/a>, one of the largest clinical studies to date in pancreatic cancer. The multisite study is currently enrolling patients recently diagnosed with Type 2 diabetes, a population with eight times the risk of developing pancreatic cancer.\n<\/p>\n<p class=\"bwmarginl1\">\n<span class=\"bwuline\">J.P. Morgan Healthcare Conference Presentation Details<br \/>\n<br \/><\/span>Date: January 11, 2023<br \/>\n<br \/>Time: 2:30 p.m. PST<br \/>\n<br \/>Location: The Westin St. Francis, Mission Bay Room\n<\/p>\n<p>\nTo learn more about the Avantect Pancreatic Cancer Test, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Favantect.com&amp;esheet=53178649&amp;newsitemid=20230109005189&amp;lan=en-US&amp;anchor=avantect.com&amp;index=3&amp;md5=2b8d958aa86222798f0ec1768108469c\" rel=\"nofollow noopener\" shape=\"rect\">avantect.com<\/a>.\n<\/p>\n<p>\n<b>About ClearNote Health<\/b>\n<\/p>\n<p>\nClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer healthier lives. Utilizing a standard blood draw, the company applies its proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases, ClearNote Health identifies cancers before they progress and when patients are most likely to benefit from treatment. ClearNote Health is headquartered in San Diego, with additional presence in the San Francisco Bay area and internationally. The company\u2019s CLIA- and CAP-accredited laboratory is located in San Diego, Calif. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clearnotehealth.com%2F&amp;esheet=53178649&amp;newsitemid=20230109005189&amp;lan=en-US&amp;anchor=www.clearnotehealth.com&amp;index=4&amp;md5=4076b01d0dcdf637114744be7a894847\" rel=\"nofollow noopener\" shape=\"rect\">www.clearnotehealth.com<\/a> or follow the company on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fclearnotehealth&amp;esheet=53178649&amp;newsitemid=20230109005189&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=408d112efc3958cfd69a80844b370a22\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a> or <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fclearnotehealth%2F&amp;esheet=53178649&amp;newsitemid=20230109005189&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=db15edffc90cb6e9a063c37192cf4aba\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nVictoria Steiner<br \/>\n<br \/><a target=\"_blank\" href=\"mailto:Vsteiner&#64;clearnot&#101;&#104;&#101;&#97;&#108;&#116;&#104;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x56;&#x73;&#x74;&#x65;&#x69;&#x6e;&#x65;&#x72;&#x40;&#x63;&#x6c;&#101;&#97;&#114;&#110;&#111;&#116;&#101;health&#x2e;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company unveils Avantect early cancer detection test portfolio SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;ClearNote Health\u2122 (formerly known as Bluestar Genomics), a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer healthier lives, today announced that Chief Executive Officer Dave Mullarkey will present a company update at the 41st annual J.P. Morgan Healthcare &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52688","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company unveils Avantect early cancer detection test portfolio SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;ClearNote Health\u2122 (formerly known as Bluestar Genomics), a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer healthier lives, today announced that Chief Executive Officer Dave Mullarkey will present a company update at the 41st annual J.P. Morgan Healthcare ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-09T13:02:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230109005189\/en\/1679727\/21\/ClearNoteHealthLogo_rgb_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2023-01-09T13:02:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":528,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005189\\\/en\\\/1679727\\\/21\\\/ClearNoteHealthLogo_rgb_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005189\\\/en\\\/1679727\\\/21\\\/ClearNoteHealthLogo_rgb_%281%29.jpg\",\"datePublished\":\"2023-01-09T13:02:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005189\\\/en\\\/1679727\\\/21\\\/ClearNoteHealthLogo_rgb_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005189\\\/en\\\/1679727\\\/21\\\/ClearNoteHealthLogo_rgb_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend","og_description":"Company unveils Avantect early cancer detection test portfolio SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;ClearNote Health\u2122 (formerly known as Bluestar Genomics), a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer healthier lives, today announced that Chief Executive Officer Dave Mullarkey will present a company update at the 41st annual J.P. Morgan Healthcare ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-09T13:02:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230109005189\/en\/1679727\/21\/ClearNoteHealthLogo_rgb_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference","datePublished":"2023-01-09T13:02:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/"},"wordCount":528,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005189\/en\/1679727\/21\/ClearNoteHealthLogo_rgb_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/","name":"ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005189\/en\/1679727\/21\/ClearNoteHealthLogo_rgb_%281%29.jpg","datePublished":"2023-01-09T13:02:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230109005189\/en\/1679727\/21\/ClearNoteHealthLogo_rgb_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230109005189\/en\/1679727\/21\/ClearNoteHealthLogo_rgb_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/clearnote-health-to-present-at-41st-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52688"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52688\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}